Skip to main content
Premium Trial:

Request an Annual Quote

Nvidia to Embed High-Performance Compute System Into Oxford Nanopore PromethIon Sequencers

NEW YORK – Nvidia said on Tuesday that it is collaborating with Oxford Nanopore Technologies to embed its DGX Station A100 high-performance computing appliance into Oxford Nanopore's PromethIon high-throughput sequencing system.

The combination of Nvidia's A100 tensor-core graphics processing units and PromethIon sequencing instruments is an attempt to "deliver the world’s most powerful sequencer that supports real-time analyses at scale, and can also analyze any length fragment of DNA/RNA," Oxford Nanopore said in a statement. The DGX A100 appliance, introduced in November, features four 80-gigabyte A100 GPUs in a single unit with 2.5 petaflops of computing power.

Oxford Nanopore did not give a release date for the combined offering but said it would be available at some point this year.

The two companies have worked together for several years, and other Oxford Nanopore sequencing systems, including the GridIon and the MinIon Mk1C, already use Nvidia GPUs.

Also, in October, Nvidia announced plans to team with Oxford Nanopore, a branch of the UK's National Health Service, as well as with King's College London, GlaxoSmithKline, and AstraZeneca to build what they expect to be Britain's most powerful supercomputer.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more